ZVRA · NASDAQ
Zevra Therapeutics, Inc.
$10.68 +0.19 (+1.88%)
Company overview
Zevra Therapeutics, Inc. is a rare disease company that discovers and develops proprietary prodrugs to treat serious medical conditions in the United States. The company leverages its Ligand Activated Therapy technology to create improved versions of FDA-approved drugs and prodrug candidates for new disease indications. Its pipeline focuses on attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. The lead product candidate KP1077, in Phase II clinical trials for idiopathic hypersomnia and narcolepsy, is based on serdexmethylphenidate, a prodrug of d-methylphenidate. The company is also developing KP879 for stimulant use disorder, which is in Phase II trials.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $634M
- Employees
- 59
- Headquarters
- Celebration, FL
- Website
- zevra.com
- CEO
- Neil F. McFarlane
- Listed
- April 16, 2015
- P/E
- 4.90
- Dividend yield
- 0.00%
Company financials
- Revenue
- $122M
- Gross profit
- $105M
- Operating income
- -$48.7M
- EBITDA
- $106M
- Net income
- $124M
- EPS
- $2.18
- Total assets
- $279M
- Total debt
- $1.1M
- Gross margin
- 85.51%
- Net margin
- 101.58%
- Earnings yield
- 20.41%
No geographic segmentation.
Showing FY 2023
ZVRA
1D
NASDAQ
O10.12H10.42L10.04C10.29+0.19 (+1.88%)Vol509.06K
News